Home
BIO
BIO News

Latest Bio-Rad Laboratories Inc. (BIO) News on February 22, 2025

Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips

Zacks

a day ago

Globus Medical Q4 Earnings & Revenues Top, Margins Expand, Stock Dips

EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y

Zacks

2 days ago

EXAS Q4 Loss Narrower Than Expected, Stock Falls, Revenues Up Y/Y

Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Zacks

3 days ago

Penumbra Q4 Earnings & Revenues Top, Margins Expand, Stock Rises

Argus Research

4 days ago

BIO: Rating increased to a HOLD

Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles

Zacks

4 days ago

Medtronic Q3 Earnings Top Estimates, Revenues Miss, Stock Tumbles

BIO Stock Might Rise Following the Offer to Acquire Stilla

Zacks

4 days ago

BIO Stock Might Rise Following the Offer to Acquire Stilla

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Zacks

5 days ago

Why This 1 Growth Stock Could Be a Great Addition to Your Portfolio

Bio-Rad price target lowered to $447 from $477 at RBC Capital

TipRanks

7 days ago

Bio-Rad price target lowered to $447 from $477 at RBC Capital

Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations

Simply Wall St.

7 days ago

Bio-Rad Laboratories Full Year 2024 Earnings: EPS Misses Expectations

Morningstar Research

8 days ago

Morningstar | A Weekly Summary of Stock Ideas and Developments in the Companies We Cover

BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

Zacks

8 days ago

BIO Q4 Earnings and Revenues Miss Estimates, Stock Down Aftermarket

Bio-Rad set to acquire Stilla Technologies

Medical Device Network

8 days ago

Bio-Rad set to acquire Stilla Technologies

Morningstar Research

8 days ago

Analyst Report: Bio-Rad Laboratories, Inc.

MT Newswires

8 days ago

UBS Adjusts Price Target on Bio-Rad Laboratories to $355 From $390, Keeps Buy Rating

MT Newswires

8 days ago

RBC Cuts Price Target on Bio-Rad Laboratories to $447 From $477, Keeps Outperform Rating

Thomson Reuters StreetEvents

8 days ago

Q4 2024 Bio Rad Laboratories Inc Earnings Call

Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls

Zacks

8 days ago

Bruker Q4 Earnings & Revenues Surpass Estimates, Stock Falls

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

GuruFocus.com

9 days ago

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ...

Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates

Zacks

9 days ago

Bio-Rad Laboratories (BIO) Misses Q4 Earnings and Revenue Estimates

Associated Press Finance

9 days ago

Bio-Rad: Q4 Earnings Snapshot

MT Newswires

9 days ago

Bio-Rad Laboratories' Q4 Adjusted Earnings, Revenue Fall

CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

Zacks

10 days ago

CVS Health Stock Up on Q4 Earnings & Revenue Beat, Margins Rise

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Report Preview: What To Look For

GuruFocus.com

10 days ago

Bio-Rad Laboratories Inc (BIO) Q4 2024 Earnings Report Preview: What To Look For

OncoCyte prices $29.1M equity offering

TipRanks

11 days ago

OncoCyte prices $29.1M equity offering

Oncocyte Prices $29.1 Million Equity Offering

GlobeNewswire

12 days ago

Oncocyte Prices $29.1 Million Equity Offering

Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises

Zacks

12 days ago

Omnicell Q4 Earnings & Revenues Beat, Stock Up, Gross Margin Rises

QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand

Zacks

15 days ago

QIAGEN Q4 Earnings Miss, Stock Crashes, Margins Expand

PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase

Zacks

15 days ago

PAHC Stock Falls Despite Q2 Earnings & Revenue Beat, Margins Increase

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Zacks

16 days ago

Earnings Preview: Bio-Rad Laboratories (BIO) Q4 Earnings Expected to Decline

Hologic Q1 Earnings Beat, Stock Falls on Dismal '25 Sales Guidance

Zacks

16 days ago

Hologic Q1 Earnings Beat, Stock Falls on Dismal '25 Sales Guidance

Argus Research

18 days ago

BIO: Lowering target price to $279.00

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

Zacks

18 days ago

Has BioRad Laboratories (BIO) Outpaced Other Medical Stocks This Year?

MT Newswires

18 days ago

RBC Trims Price Target on Bio-Rad Laboratories to $477 From $481, Keeps Outperform Rating

Argus Research

25 days ago

BIO: Raising target price to $294.00

Bio-Rad Laboratories, Inc. (BIO): Is This Healthcare Stock A Good Buy?

Insider Monkey

25 days ago

Bio-Rad Laboratories, Inc. (BIO): Is This Healthcare Stock A Good Buy?

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Business Wire

a month ago

Bio-Rad to Report Fourth Quarter and Full Year 2024 Financial Results on Thursday, February 13, 2025

Argus Research

a month ago

BIO: Lowering target price to $283.00

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Zacks

a month ago

Is Adaptive Biotechnologies (ADPT) Stock Outpacing Its Medical Peers This Year?

Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now

Zacks

a month ago

Why Bio-Rad Stock is an Apt Pick for Your Portfolio Right Now

Argus Research

a month ago

BIO: Raising target price to $294.00

MT Newswires

a month ago

Bio-Rad Laboratories Led $105 Million Series C Funding Round for Geneoscopy

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Business Wire

a month ago

Geneoscopy Closes $105M in Series C Funding Round to Power Next-Generation of Gastrointestinal Diagnostic Tests

Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

Business Wire

2 months ago

Bio-Rad’s Management to Host Investor Meetings at J.P. Morgan's 43rd Annual Healthcare Conference

At US$331, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

Simply Wall St.

2 months ago

At US$331, Is It Time To Put Bio-Rad Laboratories, Inc. (NYSE:BIO) On Your Watch List?

Argus Research

2 months ago

BIO: Rating increased to a HOLD

Argus Research

2 months ago

BIO: Lowering target price to $277.00

Argus Research

2 months ago

BIO: Lowering target price to $278.00

MT Newswires

2 months ago

RBC Raises Price Target on Bio-Rad Laboratories to $481 From $469, Keeps Outperform Rating

Argus Research

3 months ago

BIO: Raising target price to $291.00

Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?

Zacks

3 months ago

Bio-Rad (BIO) Down 5.5% Since Last Earnings Report: Can It Rebound?

Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Simply Wall St.

3 months ago

Estimating The Intrinsic Value Of Bio-Rad Laboratories, Inc. (NYSE:BIO)

Bio-Rad Laboratories, Inc. (BIO): A Bull Case Theory

Insider Monkey

3 months ago

Bio-Rad Laboratories, Inc. (BIO): A Bull Case Theory

Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

Business Wire

3 months ago

Bio-Rad’s Management to Host Investor Meetings at Citi's 2024 Global Healthcare Conference

What Makes Bio-Rad Laboratories (BIO) an Attractive Opportunity?

Insider Monkey

3 months ago

What Makes Bio-Rad Laboratories (BIO) an Attractive Opportunity?

Argus Research

3 months ago

BIO: Lowering target price to $292.00

Argus Research

4 months ago

BIO: Raising target price to $299.00

Interpreting Bio-Rad (BIO) International Revenue Trends

Zacks

4 months ago

Interpreting Bio-Rad (BIO) International Revenue Trends

Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Simply Wall St.

4 months ago

Bio-Rad Laboratories, Inc. (NYSE:BIO) Just Released Its Third-Quarter Results And Analysts Are Updating Their Estimates

Bio-Rad Laboratories Third Quarter 2024 Earnings: EPS: US$23.37 (vs US$3.65 in 3Q 2023)

Simply Wall St.

4 months ago

Bio-Rad Laboratories Third Quarter 2024 Earnings: EPS: US$23.37 (vs US$3.65 in 3Q 2023)

Thomson Reuters StreetEvents

4 months ago

Q3 2024 Bio Rad Laboratories Inc Earnings Call

Morningstar Research

4 months ago

Analyst Report: Bio-Rad Laboratories, Inc.

MT Newswires

4 months ago

UBS Adjusts Price Target on Bio-Rad Laboratories to $390 From $400, Maintains Buy Rating

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

Business Wire

4 months ago

Bio-Rad's Management to Participate in Fireside Chat During UBS Global Healthcare Conference

BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket

Zacks

4 months ago

BIO Q3 Earnings and Revenues Surpass Estimates, Stock Up Aftermarket

Bio-Rad Laboratories Inc (BIO) Q3 2024 Earnings Call Highlights: Strong Clinical Diagnostics ...

GuruFocus.com

4 months ago

Bio-Rad Laboratories Inc (BIO) Q3 2024 Earnings Call Highlights: Strong Clinical Diagnostics ...

Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates

Zacks

4 months ago

Bio-Rad Laboratories (BIO) Beats Q3 Earnings and Revenue Estimates

Associated Press Finance

4 months ago

Bio-Rad: Q3 Earnings Snapshot

Bio-Rad Reports Third-Quarter 2024 Financial Results

Business Wire

4 months ago

Bio-Rad Reports Third-Quarter 2024 Financial Results

What to Expect From These 3 MedTech Stocks This Earnings Season

Zacks

4 months ago

What to Expect From These 3 MedTech Stocks This Earnings Season

Shareholders in Bio-Rad Laboratories (NYSE:BIO) have lost 58%, as stock drops 4.6% this past week

Simply Wall St.

4 months ago

Shareholders in Bio-Rad Laboratories (NYSE:BIO) have lost 58%, as stock drops 4.6% this past week

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

Zacks

4 months ago

Analysts Estimate Bio-Rad Laboratories (BIO) to Report a Decline in Earnings: What to Look Out for

FitLife Brands (FTLF) Soars 5.7%: Is Further Upside Left in the Stock?

Zacks

4 months ago

FitLife Brands (FTLF) Soars 5.7%: Is Further Upside Left in the Stock?

BIO Gears Up for Q3 Earnings: Here's What You Need to Know

Zacks

4 months ago

BIO Gears Up for Q3 Earnings: Here's What You Need to Know

Bio-Rad Laboratories (BIO) is a Classic Ariel Stock: Ariel Fund

Insider Monkey

4 months ago

Bio-Rad Laboratories (BIO) is a Classic Ariel Stock: Ariel Fund

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

Business Wire

4 months ago

Bio-Rad to Report Third Quarter 2024 Financial Results on Wednesday, October 30, 2024

BANK OF NOVA SCOTIA's Strategic Acquisition in Bio-Rad Laboratories Inc

GuruFocus.com

4 months ago

BANK OF NOVA SCOTIA's Strategic Acquisition in Bio-Rad Laboratories Inc

Argus Research

4 months ago

BIO: Raising target price to $274.00

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

Zacks

5 months ago

Should You Continue to Hold Bio-Rad Stock in Your Portfolio?

MT Newswires

5 months ago

Citigroup Upgrades Bio-Rad Laboratories to Buy From Neutral, Adjusts Price Target to $400 From $350

Palantir Soars, Dell Pops As Big AI Plays Finally Get S&P 500 Nod

Investor's Business Daily

5 months ago

Palantir Soars, Dell Pops As Big AI Plays Finally Get S&P 500 Nod

Palantir and Dell Will Join S&P 500—What You Need To Know

Investopedia

5 months ago

Palantir and Dell Will Join S&P 500—What You Need To Know

Palantir Stock Jumps on S&P 500 Addition. Here’s Who Else Was Added.

Barrons.com

5 months ago

Palantir Stock Jumps on S&P 500 Addition. Here’s Who Else Was Added.

Palantir, Dell Will Finally Join The S&P 500. The Stocks Are Jumping.

Investor's Business Daily

6 months ago

Palantir, Dell Will Finally Join The S&P 500. The Stocks Are Jumping.

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

PR Newswire

6 months ago

Palantir Technologies, Dell Technologies, and Erie Indemnity Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600

Palantir, Dell Stocks Jump on S&P 500 Addition

Barrons.com

6 months ago

Palantir, Dell Stocks Jump on S&P 500 Addition

National Vision (EYE) Down 6.9% Since Last Earnings Report: Can It Rebound?

Zacks

6 months ago

National Vision (EYE) Down 6.9% Since Last Earnings Report: Can It Rebound?

MT Newswires

6 months ago

Wells Fargo Initiates Bio-Rad Laboratories at Equalweight With $340 Price Target

Argus Research

6 months ago

BIO: Raising target price to $283.00

Bio-Rad’s Management to Participate in Fireside Chat During Wells Fargo’s 2024 Healthcare Conference

Business Wire

6 months ago

Bio-Rad’s Management to Participate in Fireside Chat During Wells Fargo’s 2024 Healthcare Conference

Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now

Zacks

6 months ago

Reasons to Retain Bio-Rad (BIO) Stock in Your Portfolio Now

Argus Research

6 months ago

BIO: What does Argus have to say about BIO?

MT Newswires

6 months ago

Bio-Rad Laboratories Names Jon DiVincenzo COO

Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

Business Wire

6 months ago

Bio-Rad Appoints Jon DiVincenzo President, Chief Operating Officer

Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure

Zacks

6 months ago

Bio-Rad (BIO) Faces Low BioPharma Demand, Competitive Pressure

Bio-Rad Laboratories, Inc. (BIO): Should You Invest In This Organ Transplant and Diagnosis Stock Right Now?

Insider Monkey

7 months ago

Bio-Rad Laboratories, Inc. (BIO): Should You Invest In This Organ Transplant and Diagnosis Stock Right Now?

MT Newswires

7 months ago

Citigroup Adjusts Price Target on Bio-Rad Laboratories to $350 From $300

MT Newswires

7 months ago

UBS Adjusts Price Target on Bio-Rad Laboratories to $400 From $385, Maintains Buy Rating

Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered

Zacks

7 months ago

Bio-Rad (BIO) Q2 Earnings Surpass Estimates, Guidance Lowered

MT Newswires

7 months ago

RBC Trims Price Target on Bio-Rad Laboratories to $401 From $402, Keeps Outperform Rating

MT Newswires

7 months ago

Bio-Rad Laboratories Q2 Earnings Up, Revenue Lower; Updates Guidance; Shares Fall After-Hours

Share on Social Networks: